Digest Network Come funziona
Network
/
Società
Am
Non verificato

Amphista Therapeutics

Di cosa scriviamo

Annunci EconomiciBiotecnologiaPubblicità/Marketing/Media/Comunicazione

11 comunicati stampa

Guarda tutti i comunicati
25/11/2025
Biotecnologia
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics announces new AMX-883 data to be presented at the ASH Annual Meeting and Exposition and provides a business progress update
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
28/10/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
27/10/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
23/10/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
15/10/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
23/09/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
17/09/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics discloses first details of its SMARCA2 degrader program
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
16/07/2025
Biotecnologia
Annunci Economici
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
22/05/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
Amphista Therapeutics showcases cryo-EM enabled platform for discovering novel Targeted Glue™ degraders at SLAS Europe 2025
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
Press Release cover image
20/03/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
Amphista Therapeutics to present novel mechanism of action for the degradation of BRD9 using its proprietary Targeted Glue® technology at two key upcoming scientific conferences
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0